Frontiers in Genetics (Apr 2021)

A Panel of Five-lncRNA Signature as a Potential Biomarker for Predicting Survival in Gastric and Thoracic Cancers

  • Jiayue Shao,
  • Wei Lyu,
  • Jiehao Zhou,
  • Jiehao Zhou,
  • Wenhui Xu,
  • Wenhui Xu,
  • Dandan Wang,
  • Dandan Wang,
  • Shanshan Liang,
  • Shanshan Liang,
  • Jiayin Zhao,
  • Jiayin Zhao,
  • Yujing Qin,
  • Yujing Qin

DOI
https://doi.org/10.3389/fgene.2021.666155
Journal volume & issue
Vol. 12

Abstract

Read online

Dysfunctional long non-coding RNAs (lncRNAs) have been found to have carcinogenic and/or tumor inhibitory effects in the development and progression of cancer, suggesting their potential as new independent biomarkers for cancer diagnosis and prognosis. The exploration of the relationship between lncRNAs and the overall survival (OS) of different cancers opens up new prospects for tumor diagnosis and treatment. In this study, we established a five-lncRNA signature and explored its prognostic efficiency in gastric cancer (GC) and several thoracic malignancies, including breast invasive carcinoma (BRCA), esophageal carcinoma, lung adenocarcinoma, lung squamous cell carcinoma (LUSC), and thymoma (THYM). Cox regression analysis and lasso regression were used to evaluate the relationship between lncRNA expression and survival in different cancer datasets from GEO and TCGA. Kaplan-Meier survival curves indicated that risk scores characterized by a five-lncRNA signature were significantly associated with the OS of GC, BRCA, LUSC, and THYM patients. Functional enrichment analysis showed that these five lncRNAs are involved in known biological pathways related to cancer pathology. In conclusion, the five-lncRNA signature can be used as a prognostic marker to promote the diagnosis and treatment of GC and thymic malignancies.

Keywords